Supreme Court Affirms Tax Exemption for Intravenous Fluids, Dismissing Revenue Appeals and Ensuring Affordable Access.

The SC upheld the CESTAT's decision, affirming the respondents' eligibility for exemption under Notifications dated 01.03.2000 and 01.03.2001 for intravenous fluids used for electrolyte replenishment. The Court determined that the products primarily served the purpose of fluid replenishment, despite containing additional components like boric acid and chlorocresol. The appeals by the Revenue were dismissed, confirming that the exemptions were applicable as initially granted, ensuring the products remained accessible at reduced prices. All pending applications were disposed of.

---

---

Issues involved:
The issues involved in this case include the interpretation of exemption notifications related to intravenous fluids, specifically focusing on whether the products in question were eligible for exemption based on their composition and usage.

Exemption under Notification dated 01.03.2000 and 01.03.2001:
The Customs Excise & Service Tax Appellate Tribunal (CESTAT) observed that the exemption granted by the Notifications dated 01.03.2000 and 01.03.2001 for intravenous fluids used for sugar, electrolyte, or fluid replenishment should not receive a restricted interpretation. The Tribunal noted that the benefit of exemption was given in the Chennai circle, and there was no indication of a revision thereafter. The Deputy Drug Controller's letter confirmed that the products in question were essential for electrolyte replenishment, making the respondents eligible for the claimed exemption. The Revenue appealed against this order.

Contention of the Appellant:
The appellant argued that the Notification dated 01.03.2001 aimed to specify the intravenous fluids eligible for exemption based on usage for sugar, electrolyte, or fluid replenishment only. They contended that the products in question containing Boric Acid and Chlorocresol were for treating veterinary diseases, not solely for fluid replenishment. The appellant highlighted that certain judgments supported their position, emphasizing the need for a detailed examination of the product composition.

Contention of the Respondent:
The respondent argued that the products, Calcium Borogluconate and Calcium Magnesium Borogluconate, were primarily composed of sugar and electrolytes essential for fluid replenishment. They referenced the product composition specified in the license granted by the Food and Drugs Control Administration, Gujarat State, indicating the products' suitability for fluid replenishment. The addition of boric acid and chlorocresol was explained as a means to enhance product shelf life, not to change its essential purpose.

Judgment and Analysis:
The Supreme Court analyzed the composition and purpose of the products in question, emphasizing that intravenous fluids are vital for maintaining electrolyte balance in the body. The Court noted that the grant of exemption aimed to ensure accessibility of life-saving products at reduced prices. It was observed that the products predominantly consisted of glucose and electrolytes for replenishment, usable as preventive measures or during disease treatment. The Court concluded that the products retained their essential purpose of replenishment, not solely for disease treatment, thus upholding CESTAT's decision to grant exemption benefits to the respondents. The appeals were dismissed, affirming the respondents' entitlement to exemption under the relevant Notifications.

Conclusion:
The Supreme Court upheld the CESTAT's decision, ruling in favor of the respondents' eligibility for exemption under the Notifications dated 01.03.2000 and 01.03.2001. The Court found no merit in the appeals, leading to their dismissal, and disposed of any pending applications.

---